Neutropenia in Patients With Castration‐Resistant Prostate Cancer Treated Using Cabazitaxel and Prophylactic Administration of Pegfilgrastim
Kazuhiko Oshinomi, Shota Kikuchi, Masahiro Kurokawa, Toshiki Mugita, Tatsuki Inoue, Motoki Yamagishi, Yoshihiro Nakagami, Masakazu Nagata, Haruaki Sasaki, Kohzou Fuji, Masashi Morita, Takashi Fukagai · 2026
Read Neutropenia in Patients With Castration‐Resistant Prostate Cancer Treated Using Cabazitaxel and Prophylactic Administration of Pegfilgrastim by Kazuhiko Oshinomi, Shota Kikuchi, Masahiro Kurokawa, Toshiki Mugita, Tatsuki Inoue, Motoki Yamagishi, Yoshihiro Nakagami, Masakazu Nagata, Haruaki Sasaki, Kohzou Fuji, Masashi Morita, Takashi Fukagai (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13570444.txt.
Description
Kazuhiko Oshinomi and co-authors check in 2026 the real world safety of a prostate cancer drug paired with a preventive white cell booster in Japanese patients. The drug prolongs life in advanced prostate cancer that no longer answers to hormone therapy. Japanese patients, though, suffer blood side effects at higher rates than Western patients in past reports.
The booster is now routine, meant to head off fever during the dangerous low count days. The team looked back at treated patients, stressing the first cycle, when fever risk peaks. Even with prevention, fever from low counts can still occur. Their rates tell clinics how much vigilance the first cycle deserves. Honest local safety data beats borrowing foreign numbers.
Catalog record
| CREATOR | Kazuhiko Oshinomi, Shota Kikuchi, Masahiro Kurokawa, Toshiki Mugita, Tatsuki Inoue, Motoki Yamagishi, Yoshihiro Nakagami, Masakazu Nagata, Haruaki Sasaki, Kohzou Fuji, Masashi Morita, Takashi Fukagai |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |